Immuron (ASX:IMC) has been granted a trading halt by the ASX, pending details of a capital raising.
Immuron is developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases.
The halt will remain in place until the opening of trade on Tuesday 13th June 2017, or earlier if an announcement is made to the market.